Amyloid Burden and Depressive Symptom Trajectories in Older Adults at Risk of Developing Cognitive Decline

2021 ◽  
Vol 82 (5) ◽  
Author(s):  
Ismael Conejero ◽  
Jonathan Dubois ◽  
Laure-Anne Gutierrez ◽  
Julien Delrieu ◽  
Christophe Arbus ◽  
...  
Keyword(s):  
Older Adults ◽  
At Risk ◽  
Depressive Symptom ◽  
Cognitive Decline ◽  
Amyloid Burden ◽  
Symptom Trajectories

scholarly journals Trait mindfulness is associated with less amyloid, tau, and cognitive decline in individuals at risk for Alzheimer's disease

2021 ◽  
Author(s):  
Cherie Strikwerda-Brown ◽  
Hazal Ozlen ◽  
Alexa Pichet Binette ◽  
Marianne Chapleau ◽  
Natalie Marchant ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Older Adults ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Cognitive Decline ◽  
Protective Factor ◽  
Present Moment ◽  
Trait Mindfulness ◽  
Cognitive Assessments ◽  
Positron Emission

Mindfulness, defined as the ability to engage in non-judgmental awareness of the present moment, has been associated with an array of health benefits. Mindfulness may also represent a protective factor for Alzheimer's disease (AD). Here, we tested the potential protective effect of trait mindfulness on cognitive decline and AD pathology in older adults at risk of AD dementia. Measures of trait mindfulness, longitudinal cognitive assessments, and AB- and tau- positron emission tomography (PET) scans were collected in 261 nondemented older adults with a family history of AD dementia from the PREVENT-AD observational cohort study. Multivariate partial least squares analyses were used to examine relationships between combinations of different facets of trait mindfulness and (1) cognitive decline, (2) AB, and (3) tau. Higher levels of trait mindfulness, particularly mindful nonjudgment, were associated with less cognitive decline, AB, and tau. Trait mindfulness may represent a psychological protective factor for AD dementia.

O2-06-04: DOES β-AMYLOID BURDEN PREDICT COGNITIVE DECLINE STATUS IN ADULTS AT RISK FOR ALZHEIMER'S DISEASE?

2006 ◽  
Vol 14 (7S_Part_11) ◽  
pp. P632-P634
Author(s):  
Heather L. Shouel ◽  
Rebecca L. Koscik ◽  
Lindsay R. Clark ◽  
Sara Elizabeth Berman ◽  
Brad T. Christian ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
At Risk ◽  
Cognitive Decline ◽  
Amyloid Burden ◽  
Β Amyloid

scholarly journals Evaluating PROMIS(®) applied cognition items in a sample of older adults at risk for cognitive decline

2017 ◽  
Vol 247 ◽  
pp. 39-42 ◽  
Author(s):  
Molly Howland ◽  
Curtis Tatsuoka ◽  
Kathleen A. Smyth ◽  
Martha Sajatovic
Keyword(s):  
Older Adults ◽  
At Risk ◽  
Cognitive Decline

scholarly journals Awareness of cognitive decline trajectories in asymptomatic individuals at risk for AD

2020 ◽  
Author(s):  
Federica Cacciamani ◽  
Luisa Sambati ◽  
Marion Houot ◽  
Marie-Odile Habert ◽  
Bruno Dubois ◽  
...  
Keyword(s):  
At Risk ◽  
Cognitive Decline ◽  
Late Stage ◽  
Brain Metabolism ◽  
Latent Class ◽  
Amyloid Burden ◽  
Reference Class ◽  
Preclinical Phase ◽  
Asymptomatic Individuals ◽  
The Impact

Abstract BackgroundLack of awareness of cognitive decline (ACD) is common in late-stage Alzheimer's disease (AD). Recent studies showed that ACD can also be reduced in the early stages.MethodsWe performed a Latent Class Analysis to identify longitudinal changes of ACD over 3 years in 314 elderly memory-complainers and its association to amyloid burden and brain metabolism. We also analysed the impact of ACD at baseline on the cognitive scores’ evolution.Results76.8% of subjects constantly had an accurate ACD (reference class). 18.95% showed a persistent heightened ACD (“worried-well” individuals). 4.25% constantly showed low ACD. They had higher amyloid burden than the reference class, and were mostly men. We found no overall effect of baseline ACD on cognitive scores’ evolution.ConclusionsACD begins to decrease during the preclinical phase in a certain group of individuals, who are of great interest because more at risk of being affected by AD.Trial registrationThe present study was conducted as part of the INSIGHT-PreAD study. The identification number of INSIGHT-PreAD study (ID-RCB) is 2012-A01731-42

scholarly journals Hearing aids to support cognitive functions of older adults at risk of dementia: the HearCog trial- clinical protocols

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Dona M. P. Jayakody ◽  
Osvaldo P. Almeida ◽  
Andrew H. Ford ◽  
Marcus D. Atlas ◽  
Nicola T. Lautenschlager ◽  
...  
Keyword(s):  
Older Adults ◽  
At Risk ◽  
Hearing Loss ◽  
Cognitive Decline ◽  
Hearing Aids ◽  
Trial Registration ◽  
Control Group ◽  
Age Related ◽  
Randomised Controlled ◽  
The Impact

Abstract Background Globally, about 50 million people were living with dementia in 2015, with this number projected to triple by 2050. With no cure or effective treatment currently insight, it is vital that factors are identified which will help prevent or delay both age-related and pathological cognitive decline and dementia. Observational data have suggested that hearing loss is a potentially modifiable risk factor for dementia, but no conclusive evidence from randomised controlled trials is currently available. Methods The HearCog trial is a 24-month, randomised, controlled clinical trial aimed at determining whether a hearing loss intervention can delay or arrest the cognitive decline. We will randomise 180 older adults with hearing loss and mild cognitive impairment to a hearing aid or control group to determine if the fitting of hearing aids decreases the 12-month rate of cognitive decline compared with the control group. In addition, we will also determine if the expected clinical gains achieved after 12 months can be sustained over an additional 12 months and if losses experienced through the non-correction of hearing loss can be reversed with the fitting of hearing aids after 12 months. Discussion The trial will also explore the cost-effectiveness of the intervention compared to the control arm and the impact of hearing aids on anxiety, depression, physical health and quality of life. The results of this trial will clarify whether the systematic correction of hearing loss benefits cognition in older adults at risk of cognitive decline. We anticipate that our findings will have implications for clinical practice and health policy development. Trial registration Australian and New Zealand Clinical Trials Registry (ANZCTR: 12618001278224), registered on 30.07.2018.

Sign in / Sign up

Export Citation Format

Share Document